Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 2d. Annual reported cases* of notifiable diseases, by region and reporting area, United States, U.S. Territories, and Non-U.S. Residents, 2022†
Reporting Area Brucellosis Campylobacteriosis Candida auris, clinical § Carbapenemase-producing carbapenem-resistant Enterobacteriaceae Chancroid Chlamydia trachomatis infection 
U.S. Residents, excluding U.S. Territories 126 66,613 1,001 2,818 1 1,649,584
New England 3 3,398 — 66 — 53,549
Connecticut — 714 — — — 12,738
Maine 1 215 — — — 3,128
Massachusetts — 1,678 — — — 28,373
New Hampshire — 336 — 17 N 2,830
Rhode Island 2 249 — 48 — 5,199
Vermont — 206 — 1 — 1,281
Middle Atlantic 9 10,334 32 324 — 191,465
New Jersey 3 1,907 — — — 33,147
New York (excluding New York City) 5 2,720 — — — 39,845
New York City — 3,016 — 181 — 63,828
Pennsylvania 1 2,691 32 143 — 54,645
East North Central 11 8,317 615 561 — 228,510
Illinois 7 2,336 403 U — 71,564
Indiana — 988 95 245 — 33,834
Michigan 4 1,505 33 273 — 42,977
Ohio — 2,142 83 — — 54,459
Wisconsin — 1,346 1 43 — 25,676
West North Central 7 5,536 2 110 — 101,478
Iowa — 1,066 — 37 — 14,634
Kansas 1 731 — 13 — 13,935
Minnesota 5 1,539 2 42 — 22,072
Missouri — 1,178 — — — 32,346
Nebraska 1 554 — — — 9,627
North Dakota — 161 — 11 — 3,704
South Dakota — 307 — 7 — 5,160
South Atlantic 14 11,331 114 645 — 369,376
Delaware — 225 6 15 — 5,177
District of Columbia — 41 — — — 8,141
Florida 10 4,021 N N — 106,873
Georgia 2 1,586 15 257 — 72,662
Maryland — 1,092 51 — — 31,234
North Carolina 1 1,860 — 174 — 64,525
South Carolina — 634 — — — 35,525
Virginia 1 1,473 42 183 — 40,789
West Virginia — 399 — 16 — 4,450
East South Central 4 3,567 — 96 — 110,200
Alabama — 813 N N — 31,054
Kentucky 1 1,176 — — — 18,236
Mississippi — 595 — 96 — 22,968
Tennessee 3 983 — — — 37,942
West South Central 30 6,034 182 20 — 229,791
Arkansas 5 659 — U — 17,918
Louisiana 4 741 10 20 — 36,200
Oklahoma 2 1,080 — — — 20,190
Texas 19 3,554 172 U — 155,483
Mountain 7 5,370 56 509 — 117,765
Arizona 1 1,508 53 489 — 40,796
Colorado 2 1,329 — — — 26,646
Idaho — 507 — — — 5,972
Montana — 358 — — — 4,089
Nevada 2 225 3 2 — 16,189
New Mexico 1 593 — — — 11,172
Utah 1 668 — 18 — 11,108
Wyoming — 182 — — — 1,793
Pacific 41 12,726 — 487 1 247,450
Alaska — 137 — — — 5,338
California 33 9,058 N 408 1 192,647
Hawaii 2 676 — 19 — 5,530
Oregon 2 973 — 13 — 15,504
Washington 4 1,882 — 47 — 28,431
U.S. Territories 1 101 — 159 — 6,410
American Samoa — — — — — 203
Commonwealth of Northern Mariana Islands — — — — — 222
Guam 1 4 — — — 726
Puerto Rico — 97 — 159 — 4,633
U.S. Virgin Islands — — — — — 626
Non-U.S. Residents — 4 — — — 132
Total 127 66,718 1,001 2,977 1 1,656,126
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
  • U: Unavailable — The data are unavailable.
  • * Cases are assigned to the reporting jurisdiction submitting the case to NNDSS if the case's country of usual residence is the United States, a U.S. territory, unknown, or country is not reported; otherwise, the case is assigned to the Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions because this data element is only available in the HL7 generic version 2 and disease-specific message mapping guides. If a jurisdiction sends data in legacy formats, they are not able to send this information. For further information on interpretation of these data, see https://www.cdc.gov/nndss/data-statistics/readers-guides/.
  • † To calculate rates, use the populations provided in Table 8. Note that calculation of rates for the following conditions uses population subgroups as described in note #7 and population counts presented in Table 8: Zika virus infection, congenital; Zika virus disease, congenital; Infant botulism; Congenital rubella syndrome; Perinatal Hepatitis B infection; Perinatal Hepatitis C infection; Haemophilus influenzae, invasive disease; Invasive pneumococcal disease; and Influenza-associated pediatric mortality. Also see Notes #3 and #7.
  • § Note that Candida auris colonization/screening cases are not included in this table. Additionally, there may be case count discrepancies of Candida auris clinical cases reported by the NNDSS and the CDC's Mycotic Diseases Branch due to differences in data sources, reporting and aggregation methods. Please refer to the Mycotic Diseases Branch's Tracking C. auris | Candida auris (C. auris) | CDC for Candida auris case data reported by jurisdictions. These data are submitted to the CDC separately of NNDSS by jurisdictions and are published by location of the facility. Please also see Note #8.
  • ¶ Beginning in January 2022, only confirmed cases are published to align with the approved CSTE position statement 21-ID-06, whereas in previous years, all case classification statuses were published. This change may cause a decrease in published case counts when compared to previous years.
Notes:
  1. These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables. Source datasets for the 2022 annual tables were officially closed on March 29, 2024.
  2. The list of national notifiable Infectious diseases and conditions for 2022 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2022" for the notifiable condition list year, checking "Infectious" conditions, and clicking "Get Notifiable List by Year". Publication criteria for the finalized 2022 data are available at https://wonder.cdc.gov/nndss/documents/NNDSS_Publication_Criteria_2022.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  3. Population estimates for incidence rates are July 1st, 2022 postcensal estimates of the resident population of the United States for July 1, 2020, to July 1, 2022, by year, county, single year of age (range: 0 to 85+ years), bridged-race (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), Hispanic ethnicity (Hispanic or Latino, not Hispanic or Latino), and sex (Female, Male), prepared under a collaborative arrangement with the U.S. Census Bureau and the National Cancer Institute (NCI). The "Vintage 2022" population estimates for years 2020-2022 were released March 2024 by the National Cancer Institute at https://seer.cancer.gov/popdata/. For more information, see https://seer.cancer.gov/popdata/singleages.html Population estimates for territories are the 2022 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on May 02, 2024, at https://www.census.gov/data-tools/demo/idb/#/country?YR_ANIM=2022. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  4. Annual tables for 2016 and later years are available on CDC WONDER.
  5. Annual summary reports from 1993–2015 are available as published in the Morbidity and Mortality Weekly Report.
  6. NNDSS annual tables since 1952 are available at CDC Stacks. To find them, search for "NNDSS" under Collections. Once in NNDSS Collections, navigate to the "Genre" box on the left-hand side and select "Annual Reports".
  7. For most conditions, national incidence rates are calculated as the number of reported cases for each infectious disease or condition divided by the U.S. resident population for the specified demographic population or the total U.S. resident population, multiplied by 100,000. When a national notifiable infectious condition is associated with a specific age restriction, the same restriction was applied to the population in the denominator of the incidence rate calculation. In addition, population data from reporting jurisdictions in which the disease or condition was not reportable or not available were excluded from the denominator of the incidence rate calculations.

    Age restrictions in the numerator and denominator are applied for the following childhood conditions:

    • Zika virus disease, congenital (age restriction in numerator and denominator is <1 year)
    • Zika virus infection, congenital (age restriction in numerator and denominator is <1 year)
    • Haemophilus influenzae, invasive disease <5 years (age restriction in numerator and denominator is <5 years)
    • Invasive pneumococcal disease <5 years (age restriction in numerator and denominator is <5 years)
    • Influenza associated pediatric mortality (age restriction in numerator and denominator is <18 years)
    • Infant botulism (age restriction in numerator and denominator is <1 year)
    • Congenital rubella syndrome (age restriction in numerator and denominator is <1 year)
    • Perinatal hepatitis B infection (age restriction is ≤24 months)
    • Perinatal hepatitis C infection (age restriction is ≤36 months).

    Data for congenital syphilis are aggregated by the infant's year of birth. The rate for congenital syphilis is based upon the number of reported cases per 100,000 live births, using natality data for 2022 (National Center for Health Statistics Natality 2022, as compiled from data provided by the Vital Statistics Cooperative Program). Congenital syphilis cases are usually assigned to the mother's state of residence at the time of delivery. The mother's race and ethnicity are used for race- and ethnicity-specific rates of congenital syphilis cases.

  8. Surveillance data reported by other CDC programs might vary from data reported in these tables because of differences in 1) the date used to aggregate the data, 2) the timing of reports, 3) the source of the data, 4) surveillance case definitions, and 5) policies regarding case jurisdiction (i.e., which jurisdiction should submit the case notification to CDC).
  9. Disease data presented in the 2022 tables reflect impacts of the COVID-19 pandemic, such as changes in exposure-related behavior, healthcare-seeking behavior, disease reporting, and public health investigations.
Suggested Citation: Acknowledgment:
  • CDC acknowledges the local, state, and territorial health departments that collected the data from a range of case ascertainment sources (e.g., healthcare providers, hospitals, laboratories) and reported these data to CDC's National Notifiable Diseases Surveillance System.